The Company is focused on the discovery, development, manufacture and commercialization of therapeutic proteins for the treatment of human diseases.
The best Bull and Bear pitches based on recency and number of recommendations.
As of close of business on 2/20/08, this was a 5-star Morningstar stock trading at less than half of its Morningstar fair value.
Sales of Recothrom have been miserable -- the company is expecting only $7 million this year and that was probably the low hanging fruit. CEO Bruce "Jawbone" Carter has been unable to convince Wall Street that ZGEN is turning the corner and now he's… More
Read the most recent pitches from players about ZGEN.DL.
Find the members with the highest scoring picks in ZGEN.DL.
See what the Wall Street professionals think, according to their public statements and filings.